Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 1
1973 1
1978 1
1980 4
1981 3
1982 1
1983 1
1984 2
1985 2
1986 1
1987 1
1988 3
1990 1
1991 1
1992 3
1993 6
1994 5
1995 6
1996 6
1997 10
1998 10
1999 12
2000 13
2001 6
2002 11
2003 3
2004 7
2005 2
2006 10
2007 4
2008 5
2009 4
2010 11
2011 11
2012 7
2013 9
2014 9
2015 8
2016 10
2017 11
2018 13
2019 10
2020 14
2021 11
2022 15
2023 12
2024 17
2025 13
2026 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

309 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean otsuru t[au] (20 results)?
Treatment outcomes stratified by interferon profile and autoantibodies in rheumatoid arthritis.
Fukui S, Michitsuji T, Endo Y, Nishino A, Furukawa K, Shimizu T, Umeda M, Sumiyoshi R, Koga T, Iwamoto N, Tamai M, Origuchi T, van Schie KA, Ueki Y, Eiraku N, Yoshitama T, Matsuoka N, Suzuki T, Okada A, Hamada H, Ayano M, Hidaka T, Tsuru T, Huizinga TWJ, Toes REM, Kawakami A, Kawashiri SY. Fukui S, et al. Among authors: tsuru t. J Autoimmun. 2025 Dec;157:103490. doi: 10.1016/j.jaut.2025.103490. Epub 2025 Sep 30. J Autoimmun. 2025. PMID: 41027200
Comparative efficacy and safety of anifrolumab for belimumab-experienced and biologic-naïve patients with systemic lupus erythematosus: Results from the Kyushu Collagen Disease Network for Systemic Lupus Erythematosus (KCDN-SLE) registry.
Ayano M, Ueda N, Mishima K, Ota SI, Kushimoto K, Tanaka A, Doi G, Nakayama T, Maekawa M, Tsuru T, Akahoshi M, Akashi K, Horiuchi T, Niiro H. Ayano M, et al. Among authors: tsuru t. Joint Bone Spine. 2025 Jul;92(4):105882. doi: 10.1016/j.jbspin.2025.105882. Epub 2025 Mar 14. Joint Bone Spine. 2025. PMID: 40090613 No abstract available.
Clinical presentation of DFNA11 (MYO7A).
Tamagawa Y, Ishikawa K, Ishikawa K, Ishida T, Kitamura K, Makino S, Tsuru T, Ichimura K. Tamagawa Y, et al. Among authors: tsuru t. Adv Otorhinolaryngol. 2002;61:79-84. doi: 10.1159/000066808. Adv Otorhinolaryngol. 2002. PMID: 12408067 No abstract available.
Characterization of patients with rheumatoid arthritis not using biologic/targeted synthetic disease-modifying drugs despite insufficient disease control: Another difficult-to-treat RA.
Yamada H, Tsurui R, Kondo M, Fukushi JI, Sakuraba K, Miyamura T, Ishida M, Nakamura M, Inoue Y, Tsuru T, Shuto T, Yoshizawa S, Ohishi M, Kamo K, Haraguchi A, Maeyama A, Arinobu Y, Mitoma H, Ayano M, Ono N, Akasaki Y, Fujiwara T, Hara D, Arisumi S, Yasumoto K, Natori T, Niiro H, Nakashima Y. Yamada H, et al. Among authors: tsuru t. Mod Rheumatol. 2025 Sep 2;35(5):830-836. doi: 10.1093/mr/roaf037. Mod Rheumatol. 2025. PMID: 40341949
Distinct clinical outcomes based on multiple serum cytokine and chemokine profiles rather than autoantibody profiles and ultrasound findings in rheumatoid arthritis: a prospective ultrasound cohort study.
Fukui S, Michitsuji T, Endo Y, Nishino A, Furukawa K, Morimoto S, Shimizu T, Umeda M, Sumiyoshi R, Koga T, Iwamoto N, Tamai M, Origuchi T, van Schie KAJ, Ueki Y, Eiraku N, Yoshitama T, Matsuoka N, Suzuki T, Okada A, Hamada H, Ayano M, Hidaka T, Tsuru T, Maeda T, Huizinga TWJ, Toes REM, Kawakami A, Kawashiri SY. Fukui S, et al. Among authors: tsuru t. RMD Open. 2025 Jan 25;11(1):e005163. doi: 10.1136/rmdopen-2024-005163. RMD Open. 2025. PMID: 39863304 Free PMC article.
Cytokine/chemokine profiles in rheumatoid arthritis patients who failed Boolean remission solely due to elevated patient global assessment.
Fukui S, Michitsuji T, Endo Y, Nishino A, Furukawa K, Shimizu T, Umeda M, Sumiyoshi R, Koga T, Iwamoto N, Tamai M, Origuchi T, van Schie KA, Ueki Y, Eiraku N, Yoshitama T, Matsuoka N, Suzuki T, Okada A, Hamada H, Ayano M, Hidaka T, Tsuru T, Huizinga TWJ, Toes REM, Kawakami A, Kawashiri SY. Fukui S, et al. Among authors: tsuru t. Rheumatology (Oxford). 2026 Feb 4;65(2):keag020. doi: 10.1093/rheumatology/keag020. Rheumatology (Oxford). 2026. PMID: 41548226
309 results